Apimeds Pharmaceuticals US APUS
NYSE APUS
$2.25 -0.05 (-2.16%)
As of: Sep 9, 2026 · 3:59 PM EDT

Apimeds Pharmaceuticals US (APUS) Research & Development (2025 - 2026)

Apimeds Pharmaceuticals US's (APUS) quarterly Research & Development came in at $959742.0 in Q2 2026, up 47.25% on a YoY basis from $651784.0 in Q2 2025, and up 165.78% quarter-over-quarter from $361104.0 in Q4 2025.

Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo
Analysis

Apimeds Pharmaceuticals US (APUS) Research & Development (2025 - 2026) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has reported Research & Development for 2 consecutive years, with $959742.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Research & Development rose 47.25% year-over-year to $959742.0; the trailing twelve-month figure through Jun 2026 stood at $2.6 million (changed N/A YoY), and the FY2025 full-year result was $1.6 million, changed N/A from the prior year.
  • Research & Development rose to $959742.0 in Q2 2026 per APUS's latest filing, from $361104.0 in the prior quarter.
  • Across five years, Research & Development topped out at $959742.0 in Q2 2026 and bottomed at $361104.0 in Q4 2025.
Peer Set

Peer Comparison

All peers
# Company Market Cap Enterprise Value Gross Profit (Qtr) R&D (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 1.87 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 1.76 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 993.80 Mn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 1.63 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn -486.00 Mn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 651.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 413.13 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 529.60 Mn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn 202.02 Mn
10 Apimeds Pharmaceuticals US 3.79 Mn 3.79 Mn - 959,742.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 959,742.00
Dec 31, 2025 361,104.00
Sep 30, 2025 619,693.00
Jun 30, 2025 651,784.00